Drug Trial Radar · NCT05028556
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Aug 6, 2021
Primary completion
Jul 5, 2024
Study completion Sep 9, 2024
Sponsor
- Lead sponsor
- Wuhan YZY Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 31, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally advanced solid tumors.
Conditions
- Metastatic or Locally Advanced Solid Tumors
Interventions
Cohort 1 of Y101DDrug
Y101D, 1mg/kg, Q2W, intravenous infusion
Cohort 2 of Y101DDrug
Y101D, 3mg/kg, Q2W, intravenous infusion
Cohort 3 of Y101DDrug
Y101D, 10mg/kg, Q2W, intravenous infusion
Cohort 4 of Y101DDrug
Y101D, 20mg/kg, Q2W, intravenous infusion
Cohort 5 of Y101DDrug
Y101D, 30mg/kg, Q2W, intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLTs)Time frame: From the time of the first dose (Day 1) until the 2nd dosing (Day 28)
- Adverse Events according to CTCAE V5.0Time frame: Time Frame: From the start of administration to the end of the study or 28 days after the administration is stopped (up to 6 months and 28 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Cancer Prevention Center, Sun Yat-sen University
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.